Literature DB >> 20919851

SOX11 expression in mantle cell lymphoma.

Wei Xu1, Jian-Yong Li.   

Abstract

SOX11 is a transcription factor involved in embryonic neurogenesis and tissue remodeling. Its role in lymphopoiesis is still unknown. Recent studies have shown the specific overexpression of SOX11 mRNA and nuclear protein in both cyclin D1-positive and -negative mantle cell lymphoma (MCL). In addition to MCL, SOX11 is strongly expressed in hairy cell leukemia, Burkitt lymphoma, and immature lymphocytic neoplasms. Expression of SOX11 in MCL is not only a new diagnostic marker, but may also carry information related to the clinical and biological behavior. Further study of the biology may reveal common pathways to neoplasia related to SOX11 expression.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20919851     DOI： 10.3109/10428194.2010.514968

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


  11 in total

1.  Leukemic non-nodal mantle cell lymphomas have a distinct phenotype and are associated with deletion of PARP1 and 13q14.

Authors:  Mathieu Gallo; Valère Cacheux; Laure Vincent; Caroline Bret; Ariane Tempier; Caroline Guittard; Alexandra Macé; Nicolas Leventoux; Valérie Costes; Vanessa Szablewski
Journal:  Virchows Arch       Date:  2016-09-07       Impact factor: 4.064

2.  A new marker, SOX11, aids the diagnosis of mantle cell lymphoma in the prostate: A case report.

Authors:  Binghai Chen; Guangming Yin; Lujing Duan; Wanmeng Li; Xianzhen Jiang
Journal:  Oncol Lett       Date:  2012-05-25       Impact factor: 2.967

3.  Plasma cell and terminal B-cell differentiation in mantle cell lymphoma mainly occur in the SOX11-negative subtype.

Authors:  Inmaculada Ribera-Cortada; Daniel Martinez; Virginia Amador; Cristina Royo; Alba Navarro; Silvia Beà; Eva Gine; Laurence de Leval; Sergio Serrano; Andrew Wotherspoon; Dolors Colomer; Antonio Martinez; Elías Campo
Journal:  Mod Pathol       Date:  2015-09-11       Impact factor: 7.842

4.  Detection of t(12;14)(p13;q32) in a patient with IGH-CCND1 negative mantle cell lymphoma resembling ultra-high risk chronic lymphocytic leukemia.

Authors:  Yi Miao; Rong Wang; Lei Fan; Hairong Qiu; Yujie Wu; Yaoyu Chen; Wei Xu; Jianyong Li
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

5.  MiR-132-3p serves as a tumor suppressor in mantle cell lymphoma via directly targeting SOX11.

Authors:  Baoyu Wu; Jingyu Li; Han Wang; Qian Wu; Hui Liu
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2020-02-10       Impact factor: 3.000

6.  Fatty acid synthase is a key target in multiple essential tumor functions of prostate cancer: uptake of radiolabeled acetate as a predictor of the targeted therapy outcome.

Authors:  Yukie Yoshii; Takako Furukawa; Nobuyuki Oyama; Yoko Hasegawa; Yasushi Kiyono; Ryuichi Nishii; Atsuo Waki; Atsushi B Tsuji; Chizuru Sogawa; Hidekatsu Wakizaka; Toshimitsu Fukumura; Hiroshi Yoshii; Yasuhisa Fujibayashi; Jason S Lewis; Tsuneo Saga
Journal:  PLoS One       Date:  2013-05-31       Impact factor: 3.240

7.  Cytoplasmic expression of C-MYC protein is associated with risk stratification of mantle cell lymphoma.

Authors:  Yi Gong; Xi Zhang; Rui Chen; Yan Wei; Zhongmin Zou; Xinghua Chen
Journal:  PeerJ       Date:  2017-06-13       Impact factor: 2.984

8.  Sox11 Reduces Caspase-6 Cleavage and Activity.

Authors:  Elaine Waldron-Roby; Janine Hoerauf; Nicolas Arbez; Shanshan Zhu; Kirsten Kulcsar; Christopher A Ross
Journal:  PLoS One       Date:  2015-10-27       Impact factor: 3.240

9.  Cutaneous involvement as a rare first sign of systemic mantle cell lymphoma: A case report and review of the literature.

Authors:  Igor Hrgovic; Sylvia Hartmann; Björn Steffen; Thomas Vogl; Roland Kaufmann; Markus Meissner
Journal:  Mol Clin Oncol       Date:  2016-02-25

Review 10.  Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents.

Authors:  Arati A Inamdar; Andre Goy; Nehad M Ayoub; Christen Attia; Lucia Oton; Varun Taruvai; Mark Costales; Yu-Ting Lin; Andrew Pecora; K Stephen Suh
Journal:  Oncotarget       Date:  2016-07-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.